10 Jul 2007 Novavax Licenses Wyeth's Virus-Like Particle Technology
04 Jul 2007 Cytos Biotechnology reports results from phase IIa study with CYT003-QbG10 in patients suffering from atopic dermatitis
04 Jul 2007 MedImmune Begins Dosing Children Six Months to 24 Months of Age in Phase 1 Study of Vaccine to Help Prevent Two of the Most Common Viral Causes of Childhood Respiratory Illness
03 Jul 2007 Novartis enhances its vaccine pipeline by gaining access to Intercell's key technologies and vaccines programs
03 Jul 2007 DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC(TM)
28 Jun 2007 AVANT's Partner, GlaxoSmithKline, Files Rotarix(R) Application for U.S. Marketing Approval with the FDA
27 Jun 2007 Dynavax Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada
22 Jun 2007 Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin(TM) for Multiple Sclerosis
22 Jun 2007 First ad35-based HIV-1 vaccine enters Phase I clinical trial at the NIH
19 Jun 2007 Diamyd diabetes study invalidated
19 Jun 2007 Phase I for Influenza vaccine adjuvanted with Intercell’s IC31(TM) started
19 Jun 2007 New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
18 Jun 2007 Hypertension vaccine CYT006-AngQb achieves strong blood
14 Jun 2007 Novartis gains European approval for its innovative flu vaccine Optaflu(R)
14 Jun 2007 GlaxoSmithKline's application for DTaP-IPV vaccine is accepted for review by the FDA
12 Jun 2007 Opexa Presents Tovaxin(TM) Research at Federation of Clinical Immunology Societies Annual Meeting
12 Jun 2007 Orchestra Therapeutics announces new Phase II clinical data on NeuroVAX (TM) demonstrating marked expansion of regulatory T Cell populations in patients with multiple sclerosis
08 Jun 2007 Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
07 Jun 2007 All patients are enrolled in Curalogic’s clinical EU phase III trial with the ragweed product
06 Jun 2007 Encouraging clinical activity of GSK's novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer
06 Jun 2007 IDM Pharma Presents Preliminary Results from Phase II UVIDEM(R) Melanoma Vaccine Clinical Trial
06 Jun 2007 Coley Pharmaceutical Group's Vaccine Adjuvant, VaxImmune, to Enter Phase III Clinical Testing as Part of GlaxoSmithKline's Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer
05 Jun 2007 IDM Pharma Presents Interim Phase II Data From EP-2101 Lung Cancer Vaccine Clinical Trial
05 Jun 2007 Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
02 Jun 2007 Transgene to Receive First Milestone Payment of EUR 10 Million From Roche Following FDA and EMEA Review of TG 4001 (R3484) Phase III Studies Plan

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing